Progenics Pharmaceuticals Sets Second Quarter 2017 Financial Results Call for August 9
July 26 2017 - 5:00PM
Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company
developing innovative medicines and other products for targeting
and treating cancer, announced today that it will host a conference
call and webcast to review the second quarter ended June 30, 2017
financial results on Wednesday, August 9, 2017, at 8:30 a.m. ET.
To participate, please dial (877) 250-8889
(domestic) or (720) 545-0001 (international) and reference
conference ID 59855960. A live webcast will be available in the
Media Center of the Progenics website, www.progenics.com, and a
replay will be available for two weeks.
About Progenics
Progenics Pharmaceuticals, Inc. develops
innovative medicines and other technologies to target and treat
cancer. The Company's pipeline includes: 1) therapeutic agents
designed to precisely target cancer (AZEDRA® and 1095), 2)
PSMA-targeted imaging agents for prostate cancer (1404 and PyLTM),
and 3) imaging analysis tools. Progenics' first commercial product,
RELISTOR® (methylnaltrexone bromide) for opioid-induced
constipation, is partnered with Valeant Pharmaceuticals
International, Inc.
This press release may contain projections and
other "forward-looking statements" regarding future events.
Statements contained in this communication that refer to Progenics'
estimated or anticipated future results or other non-historical
facts are forward-looking statements that reflect Progenics'
current perspective of existing trends and information as of the
date of this communication. Forward looking statements generally
will be accompanied by words such as "anticipate," "believe,"
"plan," "could," "should," "estimate," "expect," "forecast,"
"outlook," "guidance," "intend," "may," "might," "will,"
"possible," "potential," "predict," "project," or other similar
words, phrases or expressions. Such statements are predictions
only, and are subject to risks and uncertainties that could cause
actual events or results to differ materially. More information
concerning Progenics and such risks and uncertainties is available
on our website, and in our press releases and reports we file with
the U.S. Securities and Exchange Commission. Progenics is providing
the information in this press release only as of its date and,
except as expressly required by law, Progenics disclaims any intent
or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
circumstances or otherwise.
Additional information concerning Progenics and
its business may be available in press releases or other public
announcements and public filings made after this release. For more
information, please visit www.progenics.com. Please follow us on
LinkedIn®. Information on or accessed through our website or social
media sites is not included in Progenics’ SEC filings.
(PGNX-F)
Contact:
Melissa Downs
Investor Relations
(646) 975-2533
mdowns@progenics.com
Progenics Pharmaceuticals (NASDAQ:PGNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Progenics Pharmaceuticals (NASDAQ:PGNX)
Historical Stock Chart
From Apr 2023 to Apr 2024